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Abstract 
American Diabetes Association [ADA] has recommended that diabetes should be diagnosed when HbA1c is 
≥6.5%. Subjects with HbA1c of 6.0 to < 6.5% were at the highest-risk for developing diabetes. Objectives: To 
determine the sensitivity and specificity of HbA1c ≥ 6.5% to diagnose Type 2 Diabetes Mellitus [T2DM] in 
overweight children and the adolescents as compared to an oral glucose tolerance test. Retrospective chart 
review was done from January 2004-December 2008, and search criteria included overweight children who had 
OGTT and HbA1c done. Based on OGGT we divided the data into normal, impaired and diabetic groups.  
 
 
------------------------------------------------------------------------ 
* Corresponding author.  
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The results shows that HbA1c cut-off of ≥ 6.5% had a specificity of 96% and a sensitivity of 40% in accurately 
diagnosing patients with T2DM. Sixty percent of T2DM and 44.60% of impaired OGTT subjects would show a 
normal glycemic status if only HbA1c is used to diagnose them. Homeostasis Model of Assessment - Insulin 
Resistance [HOMA-IR], Quantitative Insulin Sensitivity Check Index [QUICKI] and HbA1c levels were 
statistically significant between normal versus diabetic and normal versus impaired groups [p<0.05]. Due to the 
low sensitivity of the HbA1c test in diagnosing diabetes, it may result in missed or delayed diagnosis of T2DM if 
used exclusively to diagnose diabetes.  
Keywords: HbA1c; OGTT; diagnosis of Type-2 Diabetes mellitus [T2DM]; overweight children and 
adolescents 
1. Introduction 
Blood glucose measurements have been the corner stone of diagnosing diabetes. The criteria for diagnosing 
diabetes have changed over the last three decades.  WHO has published several guidelines for the diagnosis of 
diabetes since 1965 [1-3].  The oral glucose tolerance test (OGTT] has been used for over ninety years in 
clinical medicine [4]. It was in 1979 that National Diabetes Data Group [NDDG] included OGTT criteria for the 
diagnosis of diabetes with a fasting plasma glucose [FPG]  ≥126 mg/dL or a 2-h plasma glucose ≥200 mg/dL on 
more than one occasion, in a patient with classic symptoms of diabetes, a single random plasma glucose ≥200 
mg/dL is considered diagnostic [5].  The level of glycemia was chosen since it was associated with the specific 
microvascular complication of diabetic retinopathy. The 2-h plasma glucose ≥200 mg/dL was chosen based on 
the development of this diabetic complication in 77 of 1,213 subjects followed for 3–8 years after a baseline 
OGTT [6]. The International Expert Committee [IEC] proposed new diagnostic criteria based on measurement 
of HbA1c ≥6.5% for diabetes and 6.0–6.4% for “high risk” of progression to diabetes [7]. The American 
Diabetes Association [ADA] subsequently proposed HbA1c ≥6.5% for the diagnosis of diabetes and 5.7–6.4% 
for the highest risk to progress to diabetes [8].  
The potential utility of HbA1c in diabetes care is first mentioned in the 1985 WHO report [3]. Since then there 
have been arguments for and against using HbA1c for the diagnosis of diabetes.  HbA1c determination is 
convenient, does not require fasting and is not affected by day-to-day variability of glucose values e.g. stress 
and illness [9, 14]. The relationship between HbA1c and the prevalence of retinopathy is similar to that of plasma 
glucose, which was originally reported in Pima Indians [15]  and has been observed in several populations 
including Egyptians [16], NHANES study in the USA [17], Japanese [18], and Australians [19]  and more 
recently in the DETECT-2 analysis [20].  These studies were carried out in the adult population, and the HbA1c 
diagnostic cut-offs were also recommended for the children and the adolescents. There is a lack of data in the 
pediatric population regarding the utility of HbA1c in diagnosing diabetes and in identifying the individuals at a 
high risk for developing diabetes. Our study aims to determine the sensitivity and specificity of HbA1c ≥ 6.5% to 
diagnose T2DM in overweight children and the adolescents as compared to OGTT. We will also observe the 
distribution of our patient population based on having HbA1c range being normal range, high risk for developing 
diabetes r and in the diabetics.  
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2. Material and Methods 
Retrospective chart review was done from January 2004-December 2008. The search criteria included 
overweight children with BMI ≥ 85th, who had a previous OGTT and a simultaneous HbA1c. The children 
usually get one OGTT at the initial visit with a simultaneous HA1c level to determine the glycemic status. The 
study protocol was approved by The Children’s Mercy Hospitals & Clinics institutional review board.  
OGTT is done as a part of screening process for the determination of dysglycemia in overweight children BMI ≥ 
85th  percentile. Subjects may also have clinical signs of insulin resistance including acanthosis nigricans and or 
family history of T2DM in first or second-degree relatives. None of the subjects in the study had any anemia or 
hemoglobinopathies listed in their past history. These children were not on any medications for  weight loss or 
oral antihyperglycemic agents like metformin. The lifestyle of these children was sedentary with no involvement 
in an active exercise program.  Sex, race, birth weights, gestational age and maternal gestational diabetes status 
were also available in the data. 
OGTT was done at The Children’s Mercy Hospitals & Clinics [CMH], after a 10-h overnight fast. A standard 
OGTT was administered in a dose of 1.75 g of glucose per kilogram of body weight [up to a maximum of 75 g]  
was performed in all subjects to establish the glycemic status, as previously described [18].  Whole blood was 
obtained to determine the blood glucose and the HBA1c values through a peripheral venous blood draw. 
HbA1c was performed by the principle of high performance liquid chromatography [HPLC]  using a Tosoh 
Automated Glycohemoglobin Analyzer HLC-723G8 with intra- and inter-assay coefficients of variation [CVs]  
≤1.4%. Blood glucose were measured by using Analyzer: Vitros 5600 analyzer by calorimetric method with 
intra- and inter-assay CVs ≤0.8%, and insulin was measured using chemiluminescent immunoassay using iulite 
2000 system with intra- and inter-assay CVs ≤3.6%. 
Based on OGTT we divided the data into normal, impaired and diabetic groups. Impaired glucose tolerance 
[IGT] is defined as 2-h glucose after the OGTT 140–199 mg/dL. Diabetes was diagnosed based on a fasting 
glucose of >125 mg/dl or a 2-h plasma glucose ≥200 mg/dL during an OGTT [16, 17]. The prediabetes group 
included patients with either fasting glucose level between 100-125 mg/dl or IGT. The study was approved by 
the institutional review board of the Children’s Mercy Hospitals and Clinics and written consent was not 
obtained since it is a retrospective study. 
Continuous demographic variables and outcome variables were summarized by mean and standard deviation. 
We compared the continuous variables among the normal group, impaired group and diabetic group using 
Analysis of Variance [ANOVA]. Pearson and Spearman correlation coefficients were calculated between HbA1c 
and other outcome variables.  For comparison of categorical variables by group, Chi-squared analysis was used. 
We created receiver operator characteristic [ROC] curves to assess diagnosis accuracy. Multivariate analyses 
were performed using general linear model [GLM] and logistic regression. Statistical significance was claimed 
at 95% confidence level [p<0.05]. Statistical analysis was performed using SAS 9.2 [Cary, NC] and SPSS 20. 
HOMA-IR was calculated using the formula HOMA-IR= Glucose x Insulin/405, with glucose in mg/dl. 
QUICKI was calculated using the Formula: [1/log(fasting insulin micro unit/ml + 1/ log(fasting glucose mg/dl]. 
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3. Results 
A total of 628 charts were reviewed. Among these subjects, 368 [58.6%] are Caucasians, 167 [26.6%] are 
African Americans [AA] and 94 [14.9%] are mixed races, including Hispanics and Asians, etc. The 
demographic features of the groups are in [Table 1].  
Table 1:  Clinical features of the study population 
  All subjects 
(n=628) 
Normal 
(n=537) 
Impaired 
(n=78) 
Diabetic 
(n=13) 
P-value 
Age 12±3.2 11.9±3.2 12.9±2.7 13±2.9 0.01 
BMI Z-score 2.4±0.5 2.4±0.5 2.4±0.4 2.1±0.5 0.11 
OGT glucose 0 min 83.4±11.1 82.2±8.2 89±13.2 99.4±42.6 <.0001 
OGT glucose 120 min 111±32.7 101±17.6 160±17 243±38.2 <.0001 
OGT insulin 0 hr 23.6±20.5 21.8±18.9 34±24.9 37.6±30.7 <.0001 
OGT insulin 120 min 131±122 109±82 266±216 219±168 <.0001 
QUICKI 0.32±0.04 0.32±0.04 0.3±0.04 0.3±0.03 <.0001 
HOMA 5±4.6 4.5±4.1 7.6±6.2 8.1±7.8 <.0001 
Cholesterol (mg/dl) 160±34 160±34 160±30.8 184±49.4 0.06 
LDL (mg/dl) 95.1±28.6 94.8±28.6 94±26.4 115±39.6 0.06 
TG (mg/dl) 131±81.1 128±78.3 148±98 148±77.1 0.13 
HDL (mg/dl) 40.3±10 40.8±10.1 37.4±9.8 39.9±6 0.03 
ALT (U/L) 35±21.3 33.8±18.1 42.7±34.9 37.7±25.4 0.005 
AST (U/L) 31.7±16.6 31.7±16 32.9±20.4 26.7±14.1 0.51 
HbA1c (%) 5.5±0.6 5.5±0.4 5.8±0.6 6.8±1.6 <.0001 
 
HbA1c cut-off of ≥ 6.5% had a specificity of 96% and a sensitivity of 40% in accurately diagnosing patients with 
type-2 diabetes.  Sixty percent of T2DM and 44.60 % of impaired OGTT subjects would show a normal 
glycemic status if only HbA1c is used to diagnose them. There was only one subject with fasting blood glucose 
level greater than 125 mg/dl, and also had 2 hours OGTT glucose level of ≥ 200 mg/dl. Twenty nine [4.61] 
subjects had an impaired fasting glucose level and out of these six [21%] of them also had a 2 hour glucose level 
of ≥ 200 mg/dl. 
We did not detect association between HbA1c and birth weight or gestational age by univariate and multivariate 
analysis. Caucasian had significantly higher birth weights as compared to AA children [3.4 ± 0.7 vs. 3.2 ± 0.8, 
p=0.02].  There is no sex difference in HbA1c or birth weight. There was significantly positive association 
between HbA1c and diastolic blood pressure [dbp]  [spearman rho=0.14, p<0.01]. There was significant 
association between birth weight and BMI- Z score [Spearman rho=0.15, p<0.01] and between birth weight and 
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diastolic blood pressure [dbp] [Spearman rho=0.11, p=0.03].  No race and sex differences are present by 
gestational age [GA]. HOMA-IR and QUICKI were statistically significant between normal versus diabetic and 
normal versus impaired groups but not when comparing impaired versus diabetic groups [p<0.05]. GA is not 
associated with the OGTT status. No significant difference was found for BMI-z score. Small for gestational age 
[SGA] subjects are more likely to have HbA1c >5.7 [impaired or Type II] p=0.05 [60% vs. 52% vs. 78%]. There 
is very weak agreement between HbA1c status and OGTT status. When comparing Caucasians versus AA race 
groups, AA had a higher BMI Z-score, ALT and HbA1c levels [P<0.01]  [Table 2].  
Table 2:  Ethnic difference of the study population 
  Caucasian 
(n=368) 
AA 
(n=167) 
Others 
(n=94) 
P-value* 
Age 11.8±3.3 12.5±2.7 11.8±3.3 0.03 
BMI Z-score 2.4±0.6 2.4±0.4 2.4±0.6 0.70 
OGT glucose 0 min 82.8±9.7 84.3±13.4 84±11.6 0.15 
OGT glucose 120 min 111±31.1 113±34.5 113±35.3 0.44 
OGT insulin 0 hr 21.1±19.2 26.4±21.1 28.4±23 0.002 
OGT insulin 120 min 117±114 150±121 148±144 0.005 
QUICKI 0.32±0.04 0.31±0.04 0.31±0.04 0.003 
HOMA 4.4±4.3 5.6±4.9 5.9±5.2 0.004 
Cholesterol (mg/dl) 162±33.9 158±33.1 158±36.1 0.16 
LDL (mg/dl) 94.8±28 97.2±29.1 92.9±30.2 0.40 
TG (mg/dl) 145±93.3 100±52.7 136±56.4 <0.0001 
HDL (mg/dl) 40.1±9.8 41.4±10.4 39.3±10 0.21 
ALT (U/L) 35.5±17.9 29.2±12.3 44.1±37.8 0.0001 
AST (U/L) 31.5±13.3 29.1±16.5 37.9±25.1 0.10 
HbA1c (%) 5.4±0.4 5.7±0.7 5.6±0.5 <0.0001 
* compare Caucasians vs AA 
AA group had a lower triglyceride [TG] levels [P<0.01]. They also had a higher fasting glucose and insulin 
levels, and HOMA-IR and a lower QUICKI suggestive of an increased insulin resistance. [P<0.01] [Table 2].   
We calculated the weighted Kappa statistic in Tables 3 and 4 to measure agreement between HbA1c and OGTT. 
The results show that HbA1c level was more consistent with 2 hours blood glucose level on OGTT in AA as 
compared to Caucasians [Kappa: 0.06 vs. 0.27 in Table 3; 0.05 vs. 0.32 in Table 4]. 
In AA group two-hour post- glucose measurements have a stronger correlation than individual HbA1c 
measurements, which are most likely related to higher insulin resistance as shown by the HOMA-IR and the 
QUICKI values [Table-2]. Females had higher BMI z-score, triglyceride. ALT and the AST levels [Table-5]. 
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Receiver operating characteristic [ROC] curves were used to evaluate how well the A1c and baseline [0h] 
glucose can predict impaired OGTT patients defined by 2h OGTT [Figure 1].  
 
Table 3:  Comparison of subjects HA1c status and diagnosis based on the OGTT 
All subjects 
OGTT 
HbA1c < 5.7 
% 
HbA1c : 5.7-
6.49% 
HbA1c: ≥ 
6.5% 
Weighted Kappa for 
Agreement 
Normal (n=402) 278 (69.2%) 119 (29.6%) 5 (1.2%) 
0.19 (0.11 - 0.27) Impaired(n=65) 29 (44.6%) 24 (36.9%) 12 (18.5%) 
Diabetic(n=10) 2 (20%) 4 (40%) 4 (40%) 
Caucasians 
OGTT 
HbA1c < 5.7 
% 
HbA1c : 5.7-
6.49% 
HbA1c: ≥ 
6.5% 
Weighted Kappa for 
Agreement 
Normal (n=232) 175 (75.4%) 55 (23.7%) 2 (0.9%) 
0.06 (-0.05 - 0.17) Impaired(n=38) 26 (68.4%) 9 (23.7%) 3 (7.9%) 
Diabetic(n=4) 2 (50%) 2 (50%) 0 (0%) 
AA 
OGTT 
HbA1c < 5.7 
% 
HbA1c : 5.7-
6.49% 
HbA1c: ≥ 
6.5% 
Weighted Kappa for 
Agreement 
Normal (n=114) 63 (55.3%) 48 (42.1%) 3 (2.6%) 
0.27 (0.15 - 0.39) Impaired(n=20) 2 (10%) 11 (55%) 7 (35%) 
Diabetic(n=3) 0 (0%) 0 (0%) 3 (100%) 
 
Table 4:  Distribution of study subjects based on OGTT and HA1c status 
All subjects 
OGTT 
HbA1c < 6 
% 
HbA1c : 6.0-
6.49% 
HbA1c: ≥ 
6.5% 
Weighted Kappa for 
Agreement 
Normal (n=402) 
347 
(86.3%) 50 (12.4%) 5 (1.2%) 
0.22 (0.12 - 0.32) 
Impaired(n=65) 44 (67.7%) 9 (13.9%) 12 (18.5%) 
Diabetic(n=10) 4 (40%) 2 (20%) 4 (40%) 
Caucasians 
OGTT 
HbA1c < 6 
% 
HbA1c : 6.0-
6.49% 
HbA1c: ≥ 
6.5% 
Weighted Kappa for 
Agreement 
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Normal (n=232) 
208 
(89.7%) 22 (9.5%) 2 (0.9%) 
0.05 (-0.04 - 0.20) 
Impaired(n=38) 31 (81.6%) 4 (10.5%) 3 (7.9%) 
Diabetic(n=4) 3 (75%) 1 (25%) 0 (0%) 
AA 
OGTT 
HbA1c < 6 
% 
HbA1c : 6.0-
6.49% 
HbA1c: ≥ 
6.5% 
Weighted Kappa for 
Agreement 
Normal (n=114) 89 (78.1%) 22 (19.3%) 3 (2.6%) 
0.32 (0.16 - 0.48) Impaired(n=20) 9 (45%) 4 (20%) 7 (35%) 
Diabetic(n=3) 0 (0%) 0 (0%) 3 (100%) 
 
Table 5:  Gender differences of the study population 
  MALE 
(n=453) 
FEMALE 
(n=176) 
P-value 
Age 11.9±3.1 12.2±3.3 0.38 
BMI Z-score 2.3±0.5 2.6±0.6 <0.0001 
OGT glucose 0 min 82.8±12.0 84.9±8.4 0.04 
OGT glucose 120 min 111.4±33.4 111.6±30.8 0.94 
OGT insulin 0 hr 24.2±22.1 22.2±15.7 0.28 
OGT insulin 120 min 134.5±127.8 120.6±105.1 0.20 
QUICKI 0.32±0.04 0.32±0.04 0.92 
HOMA 5.0±5.0 4.7±3.5 0.44 
Cholesterol (mg/dl) 160.0±33.7 161.5±34.8 0.63 
LDL (mg/dl) 95.8±28.6 93.5±28.7 0.40 
TG (mg/dl) 122.3±70.2 154.3±100.7 <0.0001 
HDL (mg/dl) 41.2±10.0 38.1±9.7 0.001 
ALT (U/L) 32.0±16.7 42.3±28.5 <0.0001 
AST (U/L) 29.8±13.9 36.6±21.2 <0.0001 
HbA1c (%) 5.5±0.6 5.5±0.5 0.78 
 
The AUC for A1c is 0.69 [95% CI:  0.61 - 0.76], indicating A1c does not provide an accurate prediction of the 
impaired OGTT patients.  The AUC for baseline [0h] glucose is 0.66 [95% CI:  0.58 - 0.75]. There are no 
significant differences between the ROC curves for A1c and baseline [0h glucose].  ROC curve was also used to 
evaluate how well the A1c and baseline [0h) glucose can predict diabetic OGTT patients defined by 2h OGTT 
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[Figure 2].  
 
Area Under the Curve 
Test Result Variable(s) Area Std. Error P-value 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
  A1c 0.686 .037 <0.001 0.614 0.758 
OGT glucose 0 min 0.664 .044 <0.001 0.578 0.750 
Figure 1: ROC Curve for HbA1c in Prediction of Normal vs. Impaired by OGTT 2 hours 
 
The AUC for A1c is 0.85 [95% CI:  0.73 - 0.96]. Since diabetic patients are profoundly different from the 
normal subjects, we saw a better ROC curve for diabetic patients [Figure 2] as compared the impaired patients 
[Figure 1]. Despite the high AUC, there is no good cutoff for A1c that yields high sensitivity and specificity to 
predict diabetic patients. For instance, if we choose A1c cutoff as 6.05, we only have sensitivity = 0.6 and 
specificity =091. The AUC for baseline [0h] glucose is 0.78 [95% CI:  0.58 - 0.97]. 
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4. Discussion 
There are several points in favor of and against using HbA1c for diagnosing diabetes. HbA1c indicates chronic 
hyperglycemia, and can be a predictor of chronic complications of diabetes [21].  It has been shown to be better 
than FPG and 2-h OGTT in adult Saudi population when used as a screening tool for newly diagnosed diabetes 
and pre-diabetes [22]. 
 
Area Under the Curve 
Test Result Variable(s) Area Std. Error P-value 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
  A1c 0.847 0.059 <0.001 0.732 0.962 
OGT glucose 0 min 0.775 0.100 0.003 0.580 0.970 
Figure 2: ROC Curve for HbA1c in Prediction of Normal vs. Diabetic by OGTT 2 hours 
 
HbA1c can be obtained at any time of the day and can be used to guide management of diabetes [14]. It has a 
very low pre-analytical variability. Two-hour post- glucose measurements have a weaker correlation than 
individual HbA1c measurements [23].  
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However, even in western countries, the standardization of HbA1c assay is not optimal while blood glucose 
assay is standardized easily in most places of the world [10]. The cost of HbA1c assay is very high and cannot be 
used in poor and under-developed countries where the prevalence of diabetes is very high.  The diagnosis of 
diabetes may be delayed if HbA1c is used, since its measurement involves the measurement of glycation of the 
proteins, which is a result of elevated blood glucose levels. These glycation proteins may not be high enough in 
the beginning of the disease process [11]. The hemoglobin glycation can be affected by the environmental 
parameters, such as lipid peroxidation and hereditary factors [24]. HbA1c cannot be used in patients with 
abnormal hemoglobin traits or rapid turnover of the red cells [11]. It will be a bigger issue in the under 
developed countries which have a higher prevalence of anemia and hemoglobinopathies [25]. There are also 
racial differences in HbA1c levels [26]. 
The OGTT has its own drawbacks as well, the most important is a lack of reproducibility, it is inconvenient to 
perform in the clinical setting since the patient has to be fasting, does not guide about the treatment of IGT or 
diabetic patients [27]. 
The two-hour OGTT glucose levels document an impairment of β-cell function, which also correlate with 
cardiovascular disease [28].  HbA1c fails to recognize the patients with an impaired glucose tolerance test and 
has low sensitivity to diagnose diabetes [29].  
Insulin resistance precedes the development of diabetes and is a presenting feature of obesity, metabolic 
syndrome, and many cardiovascular diseases. A delayed diagnosis will mean a delay in interventions for the 
management of Diabetes which can cause multi-organ damage [12]. Contrary to HbA1c, fasting blood glucose 
and the insulin levels measured during OGTT also help in calculating the HOMA-IR and QUICKI which give 
an assessment of insulin resistance and future risk for developing diabetes [30]. 
Our study showed a sensitivity/specificity of 40%/96% in diagnosing patients with type-2 diabetes, which is 
similar to the data  Lee et al, showed that HbA1c ≥6.5% had sensitivity/specificity of 75/>99% [31]. Lee et al 
compared HbA1c with fasting plasma glucose and 2 hour OGTT glucose values for pre-diabetes and diabetes 
diagnosis in the adolescents; they showed that HbA1c had less than acceptable test performance for children with 
prediabetes. It showed lower sensitivity for diagnosing diabetes if HbA1c ≥6.5% was used. It also showed that 
two out of three patients with diabetes would be missed if the ADA recommendation of 6.5% for the diagnosis 
of diabetes was used since the subjects had HbA1c levels of 5.1 and 5.2% [31]. 
Nowicka et al showed that there was a poor agreement between HbA1c and OGTT in diagnosing diabetes in 
children and adolescents with HbA1c having a sensitivity of 62% [32].  
Our data indicate that using HbA1c exclusively for the diagnosis of diabetes will miss 40% of the diabetics and 
20% of patients at risk for developing diabetes [table 3]. This will also be true in the new onset diabetics since 
HbA1c measures the chronic hyperglycemia [10]. 
Our data also indicates that 13.4% of patients a normal OGTT may have HbA1c greater than 6%. Thirty one 
percent of patients may have an HbA1c greater than 5.7% and would have a normal OGTT status. Furthermore 
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44% of patients with HbA1c <6 % and 44.6 % with an HbA1c less than 5.7% have an impaired glycemic status 
on the OGTT.  Failure to identify these high-risk groups on HbA1c testing will cause a probable delay in 
implementing an effective prevention strategy and diagnosis of diabetes [table 4]. About 1.2 % with a normal 
OGTT and 18.5% of impaired OGTT status subjects have an HbA1c ≥ 6.5 %. Our study also showed that in AA 
group Two-hour post- glucose measurements have a stronger correlation than individual HbA1c measurements.  
The limitations of the study include its retrospective design. The data was obtained from a single-center. A 
follow-up study on the participants was not performed because of the lack of funding but it’s a possibility in the 
future. The strengths include relatively large sub-sets of obese children in the study and simultaneous HbA1c and 
OGTT measurements. 
5. Conclusion 
Due to the low sensitivity of the HbA1c test in diagnosing diabetes, it may result in missed or delayed diagnosis 
of T2DM if used exclusively to diagnose diabetes. However the use of HbA1c in AA’s may be more indicative 
of their glycemia status. 
Since the glucose level measurements are inexpensive, widely available and assays are standardized in most 
parts of the world, we recommend that OGTT should be used to diagnose diabetes using the standardized 
OGTT. W e further recommend that due to the sub-optimal reproducibility of the OGTT it should be used with 
HbA1c test to diagnose diabetes. HbA1c can be a good tool to monitor the compliance to treatment of diabetes 
and the glycemic status.  
We recommend doing further prospective studies with larger sample size to clarify and improve the 
recommendations for diagnosing diabetes. 
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